Serum IL-1β, IL-2, and IL-6 in Insulin-Dependent Diabetic Children

Yasar Dogan,1 Saadet Akarsu,1 Bilal Ustundag,2 Erdal Yilmaz,1 and Metin Kaya Gurgoze1

1Department of Pediatrics, Medical Faculty, Firat University, 23119 Elazig, Turkey
2Department of Biochemistry, Medical Faculty, Firat University, 23119 Elazig, Turkey

Received 10 July 2005; Accepted 28 October 2005

Insulin-dependent diabetes mellitus (IDDM) is a chronic disease characterized by T-cell-dependent autoimmune destruction of the insulin-producing β cells in the pancreatic islets of Langerhans, resulting in an absolute lack of insulin. T cells are activated in response to islet-dominant autoantigens, the result being the development of IDDM. Insulin is one of the islet autoantigens responsible for the activation of T-lymphocyte functions, inflammatory cytokine production, and development of IDDM. The aim of this study was to investigate serum concentrations of interleukin (IL)-1β, IL-2, IL-6, and tumor necrosis factor (TNF)-α in children IDDM. The study population consisted of 27 children with IDDM and 25 healthy controls. Children with IDDM were divided into three subgroups: (1) previously diagnosed patients (long standing IDDM) (n : 15), (2) newly diagnosed patients with diabetic ketoacidosis (before treatment) (n : 12), and (3) newly diagnosed patients with diabetic ketoacidosis (after treatment for two weeks) (n : 12). In all stages of diabetes higher levels of IL-1β and TNF-α and lower levels of IL-2 and IL-6 were detected. Our data about elevated serum IL-1β, TNF-α and decreased IL-2, IL-6 levels in newly diagnosed IDDM patients in comparison with longer standing cases supports an activation of systemic inflammatory process during early phases of IDDM which may be indicative of an ongoing β-cell destruction. Persistence of significant difference between the cases with IDDM monitored for a long time and controls in terms of IL-1β, IL-2, IL-6, and TNF-α supports continuous activation during the late stages of diabetes.

Copyright © 2006 Yasar Dogan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Recent evidence favors primary role of cellular autoimmunity and its humoral mediators in pathogenesis and following IDDM [1]. IDDM is an autoimmune disease with an inflammatory process directed against the β cells in pancreas [2]. Monocyte and type 1 T-cell-derived cytokines contribute to the pathogenesis of IDDM [3]. Chemokines play a central role in inflammatory processes by regulating leukocyte migration into sites of tissue damage [4]. Cytokines have been proposed as inducers of β-cell damage in human IDDM via the generation of nitric oxide (NO) [5].

The autoantigen insulin is responsible for stimulation in vitro of potentially hazardous memory lymphocytes to produce IL-6 and IL-10 [6]. A T helper 1 (Th1) subset of the T cells and their cytokine products (type 1 cytokines: IL-2, interferon (INF)-γ, and tumour necrosis factor (TNF)-β) dominate over an immunoregulatory Th2 subset of T cells and their cytokine products (type 2 cytokines: IL-4, IL-5, and IL-13). There is an imbalance between Th1 and Th2 subsets. This allows type 1 cytokines to initiate a cascade of immune-inflammatory processes in the islet, which includes activating macrophages to produce proinflammatory cytokines. The proinflammatory cytokines, IL-1β, IL-6, and TNF-α, have cytotoxic, cytostatic (inhibits insulin synthesis and secretion), or cytocidal actions to pancreatic islets by inducing NO production [4, 6, 7].

Recent reports suggest that the pancreas participates in TNF-α production during stress, and that the islets are predominantly responsible for such synthesis. IL-1β and TNF-α are important for the β-cell lysis in IDDM, while IL-1 receptor antagonist (IL-1ra) is considered protective by blocking the effects of IL-1 [2]. In vitro TNF-α and IL-1β inhibit insulin release from islet β cells. It appears that the process of autoimmune aggression against β cells, and its effect on insulin release and glucose homeostasis, is a slow and chronic process. However, the production of these cytokines and consequently the degree of β-cell destruction, in a genetically susceptible subject, might be enhanced by several factors including viral infections [8]. In some studies performed with newly diagnosed IDDM patients production of IL-1 was found to be increased significantly when compared with chronic IDDM patients and healthy controls. IL-1ra/IL-1 ratio decreased in patients with ND-IDDM and returned to
normal in LS-IDDM group. Circulating concentrations of IL-1ra in LS-IDDM patients have increased. Any change in TNF synthesis was not detected. This data suggests a proinflammatory imbalance in ND-IDDM patients and this may play an important role in β-cell loss [9].

The proinflammatory cytokines IL-1, IL-2, and TNF-α may play important roles alone or in combination in the pathogenesis of IDDM [10]. IL-1β and TNF-α levels can be used as indicators of continuing autoimmune aggression against β cells before the development of extensive β-cell destruction [8, 11]. Circulating IL-6, TNF-α, and CRP have been also determined as markers of the inflammatory response [12].

There is little and conflicting information regarding circulating levels and in vitro production of cytokines in diabetes. Several studies have found an increase in serum IL-6 concentrations [4, 13]; however some studies reported no difference [14] or even decreased [15] IL-6 levels. Results regarding levels and/or production of TNF-α have been inconclusive and are reported to be increased [4, 16], decreased [15], or unchanged [8, 9] as well. The effects of glycemic control on cytokines are consistent in several studies [4, 7], especially in children. The circulating levels of these cytokines in the development of type 1 DM have no conclusion in different studies.

The aim of this study was to investigate serum concentrations of IL-1β, IL-2, IL-6, and TNF-α in children IDDM.

MATERIALS AND METHODS

The study population consisted of 27 children with IDDM and 25 healthy controls. Children with IDDM were divided into three subgroups: (1) previously diagnosed patients (long standing IDDM) (n : 15), (2) newly diagnosed patients with diabetic ketoacidosis (before treatment) (n : 12), and (3) newly diagnosed patients with diabetic ketoacidosis (after treatment) (n : 12).

After the written informed parental consents were obtained, we collected the serum samples from 27 children with IDDM (12 females, 15 males) at our pediatric diabetes clinic. Subjects with any diabetic complications such as nephropathy, neuropathy or retinopathy, acute or chronic diseases, or oral medication were excluded from this study. All patients were treated with daily regular doses of insulin (1 IU/kg/d). Twenty five children without diabetes (11 females, 14 males) were recruited for the control group. The age range of the subjects was 4–17 years. Baseline features of the groups are presented in Table 1.

The background information of subjects such as age, gender, body weight, body height, daily dose of insulin injection, and disease duration were recorded. Disease duration was defined in this study as the day of initial diagnosis of diabetes to the day of blood collection. Blood samples (five milliliters) were collected using standard venipuncture technique between 9:00 and 11:00 AM. Serum samples were separated immediately after centrifugation at +4°C, 4000 rpm for 10 minutes and stored at –20°C until analysis.

Percent concentration of Hba1c in whole blood was measured with Roche diagnostics Hba1c kits with autoanalyzer (Cobas Integra 800 Autoanalyzer, Roche Diagnostics, Germany). This assay based on the immunoturbidometric determination of the stable glucose adduct to N-terminal group of the haemoglobin beta chain. Serum concentrations of cytokines such as IL-1β, IL-2, IL-6, and TNF-α were measured using commercially available enzyme-linked immunosorbent assay kits (ELISA kits, Biosource Int, Calif). All of the serum samples were analyzed in one assay in duplicate with intra- and interassay < 10%. (IL-1β sensitivity < 2 pg/mL, inter assay %4.6, intrain assay %3.4; IL-2 sensitivity <0.1 U/mL, intrain assay %7.5, intrain assay %5.7; IL-6 sensitivity < 2 pg/mL, inter assay %8.0, intrain assay %6.0; and TNF-α sensitivity < 3 pg/mL, intrain assay %9.9, intrain assay %5.2.)

STATISTICS

Data is presented as mean±SD. Comparison of variables was performed with the general linear model, student t test, or Mann-Whitney U test when necessary. Case-control differences in nominal data were evaluated with the χ2 test. Statistical analysis was performed using SPSS for Windows (SPSS Advanced Statistics 7.5, SPSS, Chicago, Ill, 1997). The comparisons of serum cytokine between children with diabetes and healthy were determined by multivariate analysis of variance (MANOVA). A simple linear correlation analysis was processed by Pearson’s method to assess the correlation between age, BMI, Hba1c, and cytokine in healthy and diabetic subjects, respectively. A forward stepwise multiple linear regression analysis was done to identify the influence of multiple variables, including age, diabetes, gender, BMI, Hba1c, and cytokine in children with diabetes and healthy, respectively. Statistical significance was assumed at P < .05.

RESULTS

In this study groups mean age and age range were as follows: control group (10.5±1.0 year) (8–13 year), LS-IDDDM group (10.6±2.1 year) (7–15 year), and ND-IDDM group (9.5±1.6 year) (6–13 year). Mean diabetes duration was 2.9±1.0 year in LS-IDDM groups. The present study was carried out to investigate serum concentrations of body mass index (BMI), Hba1c, microalbuminuria, antistreptolysin O (ASO), C-reactive protein (CRP), white blood cell (WBC), and IL-6 and TNF-α in children with IDDM (Tables 1 and 2).

As shown in Table 1, the level of glucose were significantly higher in control groups compared to LS-IDDM and ND-IDDM groups in this study (P < .01, P < .001). Hba1c levels especially were significantly higher than control group compared to LS-IDDM and ND-IDDM groups. Also there was a significantly increase in the level of microalbuminuria in diabetic groups and the positive correlation was showed between Hba1c level and microalbuminuria in diabetic groups (r : 0.71, P < .01 and r : 0.678, P < .01).

In all stages of diabetes higher levels of IL-1β and TNF-α and lower levels of IL-2 and IL-6 were detected. The results
Table 1: Baseline characteristics of the study groups (mean ± SD).

|                      | Group 1          | Group 2          | Group 3          | P-value                  |
|----------------------|------------------|------------------|------------------|--------------------------|
|                      | Control (C)      | Long standing IDDM (LS-IDDM) | Newly diagnosed IDDM (ND-IDDM) |                      |
| n                    | 25               | 15               | 12               | 12                       |
| Glucose (mg/dL)      | 84.8 ± 13.8      | 158.3 ± 21.7     | 470.9 ± 98.1a,b  | 145.5 ± 24.4             |
|                      |                  |                  |                  |                          |
| HbA1c (%)            | 5.3 ± 0.7        | 8.0 ± 1.2b       | 9.9 ± 1.4a       | 8.6 ± 1.1                |
| Microalbuminuria (mg/L) | 6.4 ± 1.0    | 8.1 ± 1.5        | 10.2 ± 3.8a      | 9.4 ± 2.9                |
| Urea (mg/dL)         | 21.8 ± 4.2a      | 30.7 ± 6.6b      | 38.1 ± 10.6      | 31.4 ± 11.8              |
| Creatinine (mg/dL)   | 0.5 ± 0.1        | 0.8 ± 0.1        | 0.9 ± 0.2a       | 0.8 ± 0.2                |
| Creatinine clearance (ml/dk) | 80.5 ± 10.6a | 56.7 ± 10.9      | 52.4 ± 13.7      | 50.1 ± 14.1              |
| ASO (U/mL)           | 0.2 ± 0.04a      | 1.5 ± 0.3        | 2.0 ± 0.5        | 1.3 ± 0.4*               |
| CRP (mg/L)           | 0.3 ± 0.04       | 0.9 ± 0.2        | 1.3 ± 0.4a       | 0.9 ± 0.3                |
| WBC (/mm³)           | 7745 ± 1412      | 12126 ± 3611a    | 9294 ± 1647      | 8548 ± 1593              |

are shown in Tables 1 and 2. There was a significantly positive correlation between the levels of IL-1β and IL-6 ($r : 0.534$, $P < .05$) and between the levels of IL-6 and TNF-α ($r : 0.565$, $P < .05$) in LS-IDDM. Also, in ND-IDDM group, a significantly positive correlation between the levels of IL-2 and IL-6 ($r : 0.698$, $P < .01$) and between the levels of IL-2 and IL-6 ($r : 0.705$, $P < .01$) was showed.

**DISCUSSION**

Chemokines play a central role in inflammatory processes by regulating leukocyte migration into sites of tissue damage [4]. Cytokines have been proposed as inducers of β-cell damage in human IDDM via the generation of NO [5]. The proinflammatory cytokines IL-6 and TNF-α are
common to both T$_{H1}$ subsets in humans [4, 10]. TNF-α and IL-6 mediated damage to micro- and macrovascular tissues, altered insulin secretion through direct or through stimulation of free fatty acid production, and altered glucose homeostasis are suggested [17, 18]. IL-6 and TNF-α are adipocyte-secreted factors [16, 17, 19]. TNF-α injection induces an increase in the concentration of plasma triglyceride and very low density lipoproteins [4]. The proinflammatory cytokine production is elevated in diabetes and in cases of elevated lipids. Diabetes induced abnormalities in fatty acid metabolism have the potential to influence macrophage cytokine release inducing upregulation of proinflammatory cytokines [20, 21]. The proinflammatory cytokines IL-1, IL-2, and TNF-α may play important roles alone or in combination in the pathogenesis of IDDM [10]. Circulating IL-6, TNF-α, and CRP have been also determined as markers of the inflammatory response [12].

The IL-2 system which involves IL-2 production, IL-2 receptor expression, and response to IL-2 is associated with autoimmune phenomena. Immunological abnormalities including autoimmune phenomena are believed to contribute to the pathogenesis of IDDM. In IDDM, IL-2 production by CD4-positive T lymphocytes within the IL-2 system is thought to be selectively defective [22]. Deficient production of IL-2 has been reported in IDDM, but its cause has not been elucidated [23, 24]. T lymphocytes are implicated in the pathogenesis of IDDM. IL-2—a T$_{H1}$ lymphocyte-derived cytokine—is at present considered to play an important role in the etiopathogenesis of IDDM. Activated T lymphocytes expressing IL-2 receptors are found at increased levels in the peripheral blood in the prediabetic period, at diagnosis and for several months after the onset of the disease, but their role in the pathogenesis of the disease is not known [25]. In previous studies with variable outcomes, IL-2 levels were found to be increased, decreased [22, 26, 27], or unchanged in patients with IDDM. These differences can be a result of different metabolic status or/and a different stage of the autoimmune process [28].

IL-2 receptors are released in the circulation in response to antigenic or mitogenic stimulation of T lymphocytes. Abnormal serum IL-2 receptor levels have been found in young children with IDDM and prediabetes. This phenomenon is acquired close to disease onset and is unlikely to be an early marker of IDDM [29]. Soluble IL-2 receptor (sIL-2R) levels reflect mononuclear cell activation and are elevated in a variety of autoimmune, neoplastic, and infectious conditions. Several investigators have studied sIL-2R levels in patients with IDDM, but results (low and elevated) have been conflicting [30].

The present study suggests the involvement of IL-2 in the pathogenesis of IDDM. In our study IL-2 levels decreased notably in all groups. Especially in patients monitored for a long time with a diagnosis of IDDM a significant decrease in IL-2 levels is a striking finding (Table 2). These results confirm

| Table 2: Specific parameters of the study groups (mean ± SD). |
|---------------------------------------------------------------|
| Group 1 | Group 2 | Group 3 |
|---------|---------|---------|
| Control (C) | Long standing IDDM (LS-IDDM) | Newly diagnosed IDDM ND-IDDM |
| n | 25 | 15 | 12 | 12 |
| Before treatment (BT) | After treatment (AT) | P-value |
| n | 25 | 15 | 12 | 12 |
| IL-1β (pg/mL) | 3.8 ± 0.9a | 12.2 ± 2.1 | 13.7 ± 2.3 | 10.7 ± 2.0 | aP < .01 |
| IL-2 (U/mL) | 7.12 ± 2.03b | 4.09 ± 1.17 | 5.78 ± 0.99a | 5.01 ± 1.93 | aP < .01 |
| IL-6 (pg/mL) | 3.08 ± 0.9a | 14.7 ± 3.1b | 9.3 ± 1.8 | 6.5 ± 1.4 | aP < .001 |
| TNF-α (pg/mL) | 5.7 ± 2.3 | 10.8 ± 13.3b | 8.0 ± 2.0a | 6.3 ± 1.5 | aP < .05 |

P-values for comparison between groups are as follows:

- C versus LS-IDDM: P < .05
- C versus ND-IDDM: P < .05
- ND-IDDM (BT versus AT): P < .05
- ND-IDDM versus C: P < .05
- LS-IDDM versus C: P < .05
- LS-IDDM versus ND-IDDM: P < .001
- ND-IDDM versus C: P < .05
- ND-IDDM versus LS-IDDM: P < .05

SD indicates standard deviation.
the presence of an imbalanced cellular immune response in IDDM patients and demonstrate that the IL-2 deficiency is already present at the diagnosis [27]. The decreased IL-2 synthesis is specific for IDDM, not explainable solely as a consequence of poor metabolic control, and thus, might be involved in the pathogenesis of the disease [31]. The low levels of IL-2 might be explained by an abnormal consumption or by the presence of increased sIL-2R levels or by a serum factor which interferes with IL-2 production [32]. These results suggest that in recent onset IDDM, IL-2-receptor-positive circulating T cells require an IL-2 supply [24].

IL-6 might play a significant role in IDDM etiopathogenesis [32]. Diabetic patients have elevated blood levels of IL-6, which is known to increase the inflammation and the development of vascular disease and atherosclerosis [33]. IL-6 levels were found to be decreased statistically significantly in any group of children with IDDM especially in newly diagnosed cases when compared with healthy controls. Even a statistically significant difference was revealed between IL-6 values related to newly diagnosed cases and those found during the posttreatment period (Table 2). In our study IL-6 levels did not reach to those of healthy children even though they rose from their lowest values in newly diagnosed cases to posttreatment values, and increased further in IDDM patients monitored for a long-term. However in some studies IL-6 levels were found to be higher in newly diagnosed cases when compared with those monitored for a long time [4]. The reports of IL-6 abnormal production in patients with IDDM are rare [25].

TNF-α remained at its highest levels in all chronic cases. Even a statistically significant difference existed between newly diagnosed cases and posttreatment group. Higher levels of TNF-α found in every stage of the disease indicate the persistence of activation of systemic immune inflammatory response [4]. In our cases levels of TNF-α increased parallel with the chronicity of the disease. However Erbagci et al [4] found higher levels in newly diagnosed cases. In contrast with our findings, Netea et al [9] revealed that TNF-α concentrations did not change in newly diagnosed cases and chronic IDDM patients.

In this study serum ASO, CRP, WBC, and proinflammatory cytokine concentrations (IL-1β, IL-6) indicated a state of chronic inflammation in all patients with IDDM. Levels of IL-1β and IL-6 in all DM groups were detected to be significantly different from those of healthy controls. TNF-α levels in all DM groups were found to be significantly different from both control and all other groups including posttreatment groups. However Erbagci et al [4] revealed that CRP, IL-6, and TNF-α levels were not different from those of control group.

Changes in interleukin levels are not limited to early stages of the disease but it persist in advanced stages. In some studies these changes were found to be restricted to only the first stage of the disease [31].

In this study we compared patients in different stages of diabetes among themselves and with healthy control group. Our data about elevated serum IL-1β, TNF-α and decreased IL-2, IL-6 levels in newly diagnosed IDDM patients in comparison with longer standing cases supports an activation of systemic inflammatory process during early phases of IDDM which may be indicative of an ongoing β-cell destruction. Persistence of significant difference between the cases with IDDM monitored for a long time and controls in terms of IL-1β, IL-2, IL-6, and TNF-α supports continuous activation during the late stages of diabetes.

REFERENCES

[1] Kukreja A, Cost G, Marker J, et al. Multiple immunoregulatory defects in type-1 diabetes. The Journal of Clinical Investigation. 2002;109(1):131–140.

[2] Karlsson Faresjo MG, Ernerudh J, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scandinavian Journal of Immunology. 2004;59(3):517–526.

[3] Hussain MJ, Maher J, Warnock T, Vats A, Peakman M, Vergani D. Cytokine overproduction in healthy first degree relatives of patients with IDDM. Diabetologia. 1998;41(3):343–349.

[4] Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel Namiduru E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clinical Biochemistry. 2001;34(8):645–650.

[5] Eizirik DL, Sandler S, Welsh N, et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. The Journal of Clinical Investigation. 1994;93(5):1968–1974.

[6] Tchorzewski H, Glowacka E, Banasik M, Lewkowicz P, Szalapska-Zawodniak M. Activated T lymphocytes from patients with high risk of type I diabetes mellitus have different ability to produce interferon-gamma, interleukin-6 and interleukin-10 and undergo anti-CD95 induced apoptosis after insulin stimulation. Immunology Letters. 2001;75(3):225–234.

[7] Rapoport MJ, Mor A, Vardi P, et al. Decreased secretion of TH2 cytokines precedes Up-regulated and delayed secretion of TH1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. Journal of Autoimmunity. 1998;11(6):635–642.

[8] El-Nawawy A, Soliman T, El-Azzouni O, et al. Interleukin-1 beta, tumor necrosis factor-alpha, insulin secretion and oral glucose tolerance in non-diabetic siblings of children with IDDM. Indian Journal of Pediatrics. 1998;65(3):455–460.

[9] Netea MG, Hancu N, Blok WJ, et al. Interleukin 1 beta, tumor necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine. 1997;9(4):284–287.

[10] Ozer G, Teker Z, Cetiner S, et al. Serum IL-1, IL-2, TNF-alpha and INF-gamma levels of patients with type 1 diabetes mellitus and their siblings. Journal of Pediatric Endocrinology & Metabolism. 2003;16(2):203–210.

[11] Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochemical Pharmacology. 1998;55(8):1139–1149.

[12] Davi G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003;107(25):3199–3203.
[13] Targher G, Zenari L, Bertolini L, Muggio M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. *Diabetes Care*. 2001;24(5):956–957.

[14] Kulseng B, Skjåk-Bræk G, Folling I, Espevik T. TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. *Scandinavian Journal of Immunology*. 1996;43(3):335–340.

[15] Geerlings SE, Brouwer EC, Van Kessel KC, van Gool W, Stolk RP, Hoepelman AI. Cytokines secretion is impaired in women with diabetes mellitus. *European Journal of Clinical Investigation*. 2000;30(11):995–1001.

[16] Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. *Life Sciences*. 2000;67(3):291–300.

[17] Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. *Molecular and Cellular Biochemistry*. 1998;182(1-2):169–175.

[18] Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. *Lancet*. 1999;353(9165):1649–1652.

[19] Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. *Molecular and Cellular Endocrinology*. 2001;175(1-2):81–92.

[20] Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. *The Journal of Clinical Investigation*. 1996;97(1):238–243.

[21] Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. *Diabetes*. 1996;45(suppl 3):S77–S80.

[22] Kretowski A, Mysliwiec J, Szelachowska M, Brzozowski C, Pietruczuk M, Kinalska I. In vitro secretion of interleukin 2 and expression of IL-2 receptor in peripheral blood lymphocytes in high risk of insulin-dependent diabetes mellitus subjects. *Archivum Immunologiae et Therapiae Experimentalis*. 1999;47(1):45–49.

[23] Shah U, Karch L, Baker L, Zier KS. Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. *The Clinical Investigator*. 1994;72(7):494–498.

[24] Gartner LA, Pfeifer MC, Albini C, Francis GL. Soluble interleukin 2 receptor levels in children with type 1 insulin-dependent diabetes mellitus. *Annals of Clinical and Laboratory Science*. 1995;25(1):44–51.

[25] Kaye WA, Adri MN, Soeldner JS, et al. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. *Diabetes*. 1984;33(6):552–555.

[26] Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. *The Journal of Clinical Investigation*. 1996;97(1):238–243.

[27] Gartner LA, Pfeifer MC, Albini C, Francis GL. Soluble interleukin 2 receptor levels in children with type 1 diabetes mellitus. *Annals of Clinical and Laboratory Science*. 1995;25(1):44–51.

[28] Kretowski A, Mysliwiec J, Szeflachowska M, Brzozowski C, Pietruczuk M, Kinalska I. In vitro secretion of interleukin 2 and expression of IL-2 receptor in peripheral blood lymphocytes in high risk of insulin-dependent diabetes mellitus subjects. *Archivum Immunologiae et Therapiae Experimentalis*. 1999;47(1):45–49.

[29] Wagner R, Bonifacio E, Bingley PJ, Genovese S, Reinwein D, Bottazzo GF. Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. *The Clinical Investigator*. 1994;72(7):494–498.

[30] Gartner LA, Pfeifer MC, Albini C, Francis GL. Soluble interleukin 2 receptor levels in children with type 1 insulin-dependent diabetes mellitus. *Annals of Clinical and Laboratory Science*. 1995;25(1):44–51.

[31] Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. *Diabetes*. 1984;33(6):552–555.

[32] Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. *The Journal of Clinical Investigation*. 1996;97(1):238–243.

[33] Gartner LA, Pfeifer MC, Albini C, Francis GL. Soluble interleukin 2 receptor levels in children with type 1 diabetes mellitus. *Annals of Clinical and Laboratory Science*. 1995;25(1):44–51.

[34] Lorini R, Montagna D, Lanfranchi A, et al. Alterations of in vitro interleukin 1 and 2 in diabetic patients. *European Journal of Pediatrics*. 1989;148(8):732–734.

[35] Hsu CY, Wang DS, Li XY, Wu WZ, Ni GC. Expression levels of IL-6 mRNA in PBMNCs from patients with IDDM, NIDDM and normals by RT-PCR procedure. *Chinese Medical Journal*. 1993;106(12):897–907.

[36] Shah U, Karch L, Baker L, Zier KS. Low interleukin-2 synthesis by type 1 diabetics is regulated at the pretranslational level. *Clinical Immunology and Immunopathology*. 1991;61(2 pt 1):177–190.

[37] Roncarolo MG, Zoppo M, Bacchetta R, et al. Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. *Clinical Immunology and Immunopathology*. 1988;49(1):53–62.